Prevalence of immunocompromised patients with a diagnosis of cytomegalovirus infection

Study identification

• EU PAS number:
  EUPAS104331
• Study ID:
  104332
• Official title and acronym:
  Prevalence of immunocompromised patients with a diagnosis of cytomegalovirus infection
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany
• Study description:
  A descriptive study of yearly prevalence of immunocompromised patients and those immunocompromised with cytomegalovirus (CMV).
• Study status:
  Finalised

Research institutions and networks

Institutions

European Medicines Agency (EMA)

Study timelines

Date when funding contract was signed

Planned:03/02/2022

Actual:03/02/2022

Study start date

Planned:03/02/2022

Actual:03/02/2022

Date of final study report

Planned:05/09/2022

Actual:02/09/2022

Sources of funding

EMA

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable